Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hyperlipidemia in the elderly].

M Farnier1

  • 1mfarnier@ipac.fr

Presse Medicale (Paris, France : 1983)
|July 4, 2001
PubMed
Summary
This summary is machine-generated.

Lipid-lowering drugs like statins may benefit elderly individuals, particularly for secondary prevention or high-risk primary prevention cases. Widespread screening for high cholesterol in the elderly is not currently recommended.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Familial hypercholesterolemia: A largely underestimated cardiovascular risk].

Annales de cardiologie et d'angeiologie·2017
Same author

Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects.

Atherosclerosis·2014
Same author

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.

Diabetes, obesity & metabolism·2011
Same author

[Recommendations for children with hypercholesterolemia].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2010
Same author

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.

International journal of clinical practice·2009
Same author

[Dyslipidemia and abdominal obesity: mechanisms and characteristics (Part I)].

Archives des maladies du coeur et des vaisseaux·2008
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Area of Science:

  • Gerontology
  • Cardiovascular Medicine
  • Pharmacology

Context:

  • Cardiovascular prevention trials have established statin efficacy in adults, but specific data for the elderly is limited.
  • Cholesterol and cardiovascular risk relationships are complex in older adults, necessitating tailored risk assessment.
  • Existing evidence suggests potential benefits of lipid-lowering therapy in specific elderly subpopulations.

Purpose:

  • To review the current evidence and clinical experience regarding lipid-lowering strategies in the elderly.
  • To provide recommendations for primary and secondary cardiovascular prevention in older adults.
  • To address the complexities of cholesterol management and cardiovascular risk in geriatric populations.

Summary:

  • While direct evidence is evolving, lipid-lowering treatments, including statins, show promise for cardiovascular risk reduction in the elderly.

Related Experiment Videos

  • Secondary prevention and high-risk primary prevention in individuals over 70 may warrant lipid-lowering therapy.
  • Routine screening for hypercholesterolemia in primary prevention for all elderly individuals is not supported by current data.

    • Impact:

    • Informs clinical decision-making for managing cardiovascular risk in older adults.
    • Highlights the need for individualized treatment approaches based on overall cardiovascular risk.
    • Guides future research directions for lipid management in geriatric populations.